bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Barclays increased their target price on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Wells Fargo & Company decreased their price objective on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, February 24th. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $4.08 on Friday. bluebird bio has a one year low of $3.56 and a one year high of $28.60. The company has a market capitalization of $39.67 million, a PE ratio of -0.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.33 and a current ratio of 0.51. The company has a 50-day simple moving average of $5.53 and a two-hundred day simple moving average of $7.73.

Institutional Investors Weigh In On bluebird bio

A number of large investors have recently made changes to their positions in BLUE. Regeneron Pharmaceuticals Inc. purchased a new position in bluebird bio in the 4th quarter worth $175,000. Verition Fund Management LLC acquired a new position in shares of bluebird bio in the third quarter valued at about $42,000. Captrust Financial Advisors raised its stake in shares of bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares during the last quarter. Barclays PLC lifted its holdings in shares of bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 184,605 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in bluebird bio by 2,270.2% in the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 355,562 shares during the last quarter. 87.43% of the stock is owned by hedge funds and other institutional investors.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.